Cancer

PUBLISHER: KuicK Research | PRODUCT CODE: 1750227

PUBLISHER: KuicK Research | PRODUCT CODE: 1750227

Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031

PUBLISHED: June 1, 2025

PAGES: 210 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031 Report Conclusions:

Gamma Delta T Cell Therapies In Clinical Trials: > 25 Therapies
Highest Phase Of Development: Phase II/III
As Of June'2025 No Gamma Delta T Cells Therapy Is Commercially Available
US & China Dominating Gamma Delta T Cell Therapies Clinical Trials Landscape: > 20 Therapies
Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication and Phase
Gamma Delta T Cell Therapies Technology Platforms Insight By Company : > 15 Platforms
Gamma Delta T Cell Therapy Market Potential By Indications Based On Adoption Rates

Adoptive gamma delta (Yδ) T cell therapy is a novel type of immunotherapy that utilizes a unique subset of T cells to recognize and destroy cancer cells. While typical alpha-beta (aB) T cells identify antigens presented by major histocompatibility complex (MHC) molecules, Yδ T cells are activated by stress induced ligands and phosphoantigens in an MHC independent fashion. This enables them to detect and target a wide variety of tumor types, including those that are not targeted by conventional immune vigilance. Yδ T cells possess characteristics of both innate and adaptive immunity, allowing them to have the ability for immediate response and immune memory, which make them particularly good candidates for off-the-shelf adoptive cell therapies.

In cancer, Yδ T cells are under investigation for their potential to destroy malignant cells without the requirement of tumor-specific antigens or genetic modifications, which are technically demanding and expensive. Their intrinsic cytotoxicity, along with the possibility of allogeneic utilization (from healthy donors), provides access to the availability of mass producible, inexpensive therapies. The majority of clinical research and development to date has been in hematological malignancies, where they have been especially promising. Yδ T cells are able to penetrate the bone marrow and other lymphoid organs and exert tumor effects there through cytokine release, direct cytotoxicity, and changing the microenvironment of the tumor.

The demand for novel cancer therapies is pressing, especially in blood cancers like acute myeloid leukemia (AML), which tend to relapse or are resistant to conventional therapies. Options for patients who relapse following remission or who have residual disease (MRD) are limited, and prognosis is usually poor. Yδ T cell therapies are in a unique position to bridge this gap, providing a potentially effective, safe, and off-the-shelf product that can be delivered without the logistical issues of autologous T cell therapies, including manufacturing hold-ups or patient variability.

TC Biopharm is leading the way in clinical development in this area. The company's most advanced product candidate, OmnImmune (formerly TCB-002), is in a pivotal Phase 2/3 trial for AML. OmnImmune is an allogeneic Yδ T cell therapy engineered to quickly target and destroy cancer cells while avoiding damage to normal tissue. This clinical program is one of the most advanced in the global Yδ T cell pipeline, highlighting TC Biopharm's growing leadership within the domain. Besides OmnImmune, the company has a number of other Yδ T cell candidates in development for various cancer indications.

One of the most significant recent advances from TC Biopharm is the development of its candidate TCB008, which is under investigation in the Phase 2 ACHIEVE trial. The firm reported in June 2025 that the first patient in Cohort B, who had relapsed previously with detectable MRD, reached complete molecular remission following two doses. A lack of detectable NPM1 transcripts after treatment signifies a profound and lasting response, which identifies TCB008 as a promising post-remission therapy for blood cancers. This achievement demarcates the potent, targeted immune function of Yδ T cells and substantiates their role as a new therapeutic strategy.

Globally, most of the research studies on Yδ T cells remains on hematologic malignancies, and there are fewer programs directed at solid tumors. This is partly a result of the more sophisticated microenvironments and the immune evasion mechanisms utilized by solid cancers. However, attempts are being made to apply Yδ T cell treatments to these more difficult contexts. Geographically, US-based players dominate the Yδ T cell therapy market, followed by increasing numbers of Chinese firms. These regions have made heavy investment in cell therapy facilities and technology, facilitating quicker translation from bench to bedside.

Moving forward, the prospects for Yδ T cell therapy are bright but will necessitate continued clinical validation, most importantly in solid tumors. With advances in manufacturing technologies and biomarker-driven strategies, the use of Yδ T cells may extend to more types of cancers. With leaders such as TC Biopharm at the forefront, the field is on track to provide life changing treatments for critical unmet needs in cancer domain.

1. Introduction To Gamma Delta T Cell Therapy

1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview of Gamma Delta T Cell Therapy
1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies

2. Role of Gamma Delta T Cells in Cancer

2.1 Gamma Delta T Cells in Cancer Progression
2.2 Anti Tumor Activity of Gamma Delta T Cells
2.3 Adopted Approaches for Gamma Delta T Cell Therapy

3. Advanced Combination Strategies In Gamma Delta T Cell Therapy

4. Gamma Delta T Cell Therapy Market Overview

4.1 Current Market Scenario
4.2 Future R&D & Commercial Opportunities
4.3 Market Potential of Gamma Delta T Cell Therapy Market
4.4 Technology Platforms For Gamma Delta T Cell Therapy
4.5 Favorable Market Growth Parameters
4.6 Key Challenges To Overcome For Future Growth

5. Global Gamma Delta T Cell Therapy Clinical Trials Overview

5.1 By Phase
5.2 By Country
5.3 By Company
5.4 By Indication
5.5 By Priority Status

6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III

7. Gamma Delta T Cell Therapy In Leukemia

7.1 Ongoing Clinical Research & Development Trends
7.2 Future Market Opportunity of Gamma Delta T Cells In Leukemia

8. Gamma Delta T Cell Therapy In Lung Cancer

8.1 Ongoing Clinical Research & Development Trends
8.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Lung Cancer

9. Gamma Delta T Cells In Breast Cancer

9.1 Ongoing Clinical Research & Development Trends
9.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Breast Cancer

10. Gamma Delta T Cells in Colorectal Cancer

10.1 Ongoing Clinical Research & Development Trends
10.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

11. Gamma Delta T Cells In Pancreatic Cancer

11.1 Ongoing Clinical Research & Development Trends
11.2 Future Market Potential of Gamma Delta Therapy In Pancreatic Cancer

12. Gamma Delta T Cells In Lymphoma

12.1 Ongoing Clinical Research & Development Trends
12.2 Future Market Potential of Gamma Delta Therapy In Lymphoma

13. Gamma Delta T Cell Therapy In Brain Tumors

13.1 Research & Development In Brain Tumors
13.2 Future Market Potential of Gamma Delta Therapy In Brain Tumors

14. Gamma Delta T Cell Therapy In Head & Neck Cancer

14.1 Research & Development In Head & Neck Cancer
14.2 Future Market Potential of Gamma Delta Therapy In Head & Neck Cancer

15. Competitive Landscape

15.1 Acepodia
15.2 Adicet
15.3 Appia Bio
15.4 Cytomed Therapeutics
15.5 Century Therapeutics
15.6 Expression Therapeutics
15.7 Immatics
15.8 IN8bio
15.9 JY BioMed
15.10 Legend Biotech
15.11 Luminary Therapeutics
15.12 PhosphoGam
15.13 Takeda
15.14 TC Biopharm
15.15 ViGenCell

List of Figures

Figure 1-1: History Of T Cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 1-4: CAR T Cell Therapy Limitations
Figure 1-5: Limitations of TIL
Figure 1-6: Limitations of Monoclonal Antibodies
Figure 1-7: Drawbacks of Chemotherapeutic Drugs
Figure 2-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 2-2: Antigen Presentation Functions Of Gamma Delta T Cells
Figure 2-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 2-4: Gamma Delta T Cell Bispecific Antibodies - Mechanism of Action
Figure 2-5: Functional Advantages Of Yo T Cells for CAR T Cancer Therapy
Figure 2-6: CAR Yo T Cells - Mechanism of Action
Figure 4-1: Gamma Delta T Cell Therapy Market - Future Opportunities
Figure 4-2: Global - Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-3: Global - Gamma Delta T Cell Therapy Market Opportunity By 1% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-4: Global - Gamma Delta T Cell Therapy Market Opportunity By 2% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-5: Global - Gamma Delta T Cell Therapy Market Opportunity By 3% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-6: Global - Gamma Delta T Cell Therapy Market Opportunity By 4% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-7: Global - Gamma Delta T Cell Therapy Market Opportunity By 5% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-8: Global - Gamma Delta T Cell Therapy Market Opportunity By 6% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-9: Global - Gamma Delta T Cell Therapy Market Opportunity By 7% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-10: Global - Gamma Delta T Cell Therapy Market Opportunity By 8% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-11: Global - Gamma Delta T Cell Therapy Market Opportunity By 9% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-12: Global - Gamma Delta T Cell Therapy Market Opportunity By 10% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-13: IN8bio - DeltEx DRI Auto
Figure 4-14: Diamond AI - Prediction Engine
Figure 4-15: Diamond AI - Immune Surveillance
Figure 4-16: Acepodia - Antibody-Cell Conjugation
Figure 4-17: Lava Therapeutics - Gammabody Platform
Figure 4-18: Adicet Bio - Gamma Delta Cell Platform
Figure 4-19: ADI-001 - Gamma Delta Cell Therapy
Figure 4-20: Century Therapeutics - Allo-Evasion
Figure 4-21: ViGenCell - ViRanger Platform
Figure 4-22: Legend Biotech - CAR-Yo T Platform
Figure 4-23: Immatics - ACTallo(R) Manufacturing Process
Figure 4-24: Gamma Delta T Cell Platform - carxall
Figure 4-25: Proprietary Manufacturing & Cell Platform Process - Adicet Bio
Figure 4-26: CAR-Yo T Cell - CytoMed Therapeutics
Figure 4-27: iPSC-Yo NKT Cells - CytoMed Therapeutics
Figure 4-28: Luminary Therapeutics - TcBuster Benefits
Figure 4-29: SSC Cell Platform - Core Foundations
Figure 4-30: Acua Platform - Appia Bio
Figure 4-31: Gamma Delta T Cell Therapy Market Drivers & Opportunities
Figure 4-32: Gamma Delta T Cell Therapy Market Challenges & Restraints
Figure 5-1: Global - Gamma Delta T Cell Therapy Clinical Trials By Phase (Numbers), 2025 Till 2031
Figure 5-2: Global - Gamma Delta T Cell Therapy Clinical Trials By Country (Numbers), 2025 Till 2031
Figure 5-3: Global - Gamma Delta T Cell Therapy Clinical Trials By Company (Numbers), 2025 Till 2031
Figure 5-4: Global - Gamma Delta T Cell Therapy Clinical Trials By Indication (Numbers), 2025 Till 2031
Figure 5-5: Global - Gamma Delta T Cell Therapy Clinical Trials By Priority Status (Numbers), 2025 Till 2031
Figure 7-1: Benefits of Gamma Delta T Cells in Leukemia
Figure 7-2: CD33CART Phase 1/2 (NCT03971799) Study - Initiation & Completion Year
Figure 7-3: ACHIEVE (TCB008-001) Phase 2 (NCT05358808) Study - Initiation & Completion Year
Figure 7-4: ACHIEVE2 (TCB008-003) Phase 1 (NCT06463327) Study - Initiation & Completion Year
Figure 7-5: INB-100 Phase 1 (NCT03533816) Study - Initiation & Completion Year
Figure 7-6: Mechanism of Action of VY9/CD123 Bispecific Antibody
Figure 7-7: Global - Estimated Leukemia Cases, 2025-2031
Figure 7-8: US - Estimated Leukemia Cases, 2025-2031
Figure 7-9: Europe - Estimated Leukemia Cases, 2025-2031
Figure 7-10: China - Estimated Leukemia Cases, 2025-2031
Figure 7-11: Japan - Estimated Leukemia Cases, 2025-2031
Figure 8-1: Role of Gamma Delta T Cells in Lung Cancer
Figure 8-2: DELTACEL-01 Phase 1 (NCT06069570) Study - Initiation & Completion Year
Figure 8-3: Global - Estimated Lung Cancer Cases, 2025-2031
Figure 8-4: US - Estimated Lung Cancer Cases, 2025-2031
Figure 8-5: Europe - Estimated Lung Cancer Cases, 2025-2031
Figure 8-6: China - Estimated Lung Cancer Cases, 2025-2031
Figure 8-7: Japan - Estimated Lung Cancer Cases, 2025-2031
Figure 9-1: Global - Estimated Breast Cancer Cases, 2025-2031
Figure 9-2: US - Estimated Breast Cancer Cases, 2025-2031
Figure 9-3: Europe - Estimated Breast Cancer Cases, 2025-2031
Figure 9-4: China - Estimated Breast Cancer Cases, 2025-2031
Figure 9-5: Japan - Estimated Breast Cancer Cases, 2025-2031
Figure 10-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 10-2: Mechanism Underlying B7-H3 Regulating Yo T Cells Killing Colon Cancer Cells
Figure 10-3: SGNEGFRd2-001 Phase I (NCT05983133) Study - Initiation & Completion Year
Figure 10-4: Global - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-5: US - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-6: Europe - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-7: China - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-8: Japan - Estimated Colorectal Cancer Cases, 2025-2031
Figure 11-1: Auspicious Outcomes Gamma Delta T Cell Therapy
Figure 11-2: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 11-3: Global - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-4: US - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-5: Europe - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-6: China - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-7: Japan - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 12-1: ACE1831 Phase I (NCT05653271) Study - Initiation & Completion Year
Figure 12-2: ADI-001 Phase I (NCT04735471) Study - Initiation & Completion Year
Figure 12-3: Global - Estimated Lymphoma Cases, 2025-2031
Figure 12-4: US - Estimated Lymphoma Cases, 2025-2031
Figure 12-5: Europe - Estimated Lymphoma Cases, 2025-2031
Figure 12-6: China - Estimated Lymphoma Cases, 2025-2031
Figure 12-7: Japan - Estimated Lymphoma Cases, 2025-2031
Figure 13-1: INB-400 Phase 1/2 (NCT05664243) Study - Initiation & Completion Year
Figure 13-2: IN8bio - Autologous (INB-400) & Allogeneic (INB-410) Candidates
Figure 13-3: UAB 1773 Phase 1 (NCT04165941) Study - Initiation & Completion Year
Figure 13-4: Global - Estimated Brain Cancer Cases, 2025-2031
Figure 13-5: US - Estimated Brain Tumor Cases, 2025-2031
Figure 13-6: Europe - Estimated Brain Tumor Cases, 2025-2031
Figure 13-7: China - Estimated Brain Tumor Cases, 2025-2031
Figure 13-8: Japan - Estimated Brain Tumor Cases, 2025-2031
Figure 14-1: Acepodia Biotech Clinical Pipeline Insight
Figure 14-2: Pfizer & Lava Therapeutics Collaboration
Figure 14-3: SGN-EGFRd2 Phase 1 (NCT05983133) Study - Initiation & Completion Year
Figure 14-4: Global - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-5: US - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-6: Europe - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-7: China - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-8: Japan - Estimated Head & Neck Cancer Cases, 2025-2031

List of Tables

Table 3-1: Ongoing Clinical Trials For Combination Of Gamma Delta T Cell Therapy
Table 7-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 8-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 9-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 10-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 11-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 12-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 13-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 14-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031
Table 14-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031

Description

Table of Contents

List of Tables

Table of Contents

1. Introduction To Gamma Delta T Cell Therapy

2. Role of Gamma Delta T Cells in Cancer

3. Advanced Combination Strategies In Gamma Delta T Cell Therapy

4. Gamma Delta T Cell Therapy Market Overview

5. Global Gamma Delta T Cell Therapy Clinical Trials Overview

6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase

7. Gamma Delta T Cell Therapy In Leukemia

8. Gamma Delta T Cell Therapy In Lung Cancer

9. Gamma Delta T Cells In Breast Cancer

10. Gamma Delta T Cells in Colorectal Cancer

11. Gamma Delta T Cells In Pancreatic Cancer

12. Gamma Delta T Cells In Lymphoma

13. Gamma Delta T Cell Therapy In Brain Tumors

14. Gamma Delta T Cell Therapy In Head & Neck Cancer

15. Competitive Landscape

List of Figures

List of Tables